CSL Shares Double Off Lows, In Year of Two Halves

CSL shares (ASX: CSL) has delivered one of the more dramatic recoveries on the ASX this year, with shares jumping more than 93% off their June 2026 lows to close above A$180 for the first time since the stock’s brutal first-half selloff.

The CSL share price closed at A$181.91 to start the week, gaining 2.8% on the day to cap a remarkable second-half recovery that has seen the stock more than double from its 52-week low of A$90.00. At that point, CSL had shed more than 45% of its value through the first half of calendar 2026, weighed down by a toxic combination of margin pressure, Vifor write-down concerns, and a broader de-rating of global healthcare stocks. The year of two halves continues, with bulls taking over.

Driving CSL shares higher

Whilst shares had already been climbing off the worst of the selling, the major jump came following CSL’s FY26 full-year results, released in mid-August. CSL reported a statutory net loss of US$2.6 billion for the year, driven by pre-tax non-cash impairment charges of US$7.1 billion on its troubled Vifor acquisition, alongside restructuring costs that have been building for several quarters. For a company that had long been regarded as a blue-chip compounder, the statutory loss was a jarring headline.

But beneath the write-downs, the operational picture told a different story. Underlying Net Profit After Tax and Amortisation, the metric CSL uses to strip out non-cash items and give markets a cleaner read on recurring earnings power, came in at US$3.1 billion, down just 2% year-on-year. More importantly, management’s guidance for FY27 materially outpaced what analysts had pencilled in. CSL projected approximately 5% underlying NPAT growth for the coming financial year, well ahead of market consensus estimates sitting around 2%. That gap between guidance and expectation was the trigger for the re-rating that followed.

The recovery in CSL Behring, the company’s flagship blood plasma division, added further credibility to the turnaround story. The division had been under significant pressure through the first half of FY26, as US inventory oversupply and widespread destocking across the immunoglobulin market weighed heavily on sales volumes and pricing. By the second half of the year, those headwinds had largely cleared. Full-year immunoglobulin sales expanded 7% year-on-year, signalling that end-user demand for plasma-derived therapies remains structurally intact. The hereditary angioedema treatment Andembry was another bright spot, recording US$240 million in sales for the year and exceeding initial guidance.

Complementing the operational recovery is an aggressive cost-reduction program that management unveiled alongside the full-year results. The initiative targets US$400 million in annualised cost savings by FY27, scaling to US$550 million per annum by FY28. The program spans corporate restructuring, manufacturing efficiency improvements, and overhead reduction across the global business. For a company with CSL’s cost base, the scale of the savings is meaningful and provides a direct lever for margin expansion even in an environment where top-line revenue growth remains modest.

What Lay Ahead?

On the institutional side, research from Morgan Stanley noted that active Australian fund managers had aggressively increased their overweight positions in CSL during August and September, making healthcare the most favoured sector on the ASX during that period. The institutional re-allocation has been a meaningful driver of the share price recovery, as large funds that had reduced exposure during the first-half selloff moved to rebuild positions ahead of what they expect to be a sustained earnings recovery cycle. A further positive came from CSL completing voluntary drug pricing agreements with the US government alongside other global pharmaceutical companies, reducing one of the more significant regulatory overhangs that had weighed on the stock earlier in the year.

The bear case is not without substance, as Vifor remains a structural headache. Iron product revenues within the division are projected to fall approximately 25% due to generic competition entering the market, and the US$7.1 billion impairment charge has already demonstrated the acquisition’s failure to deliver the value CSL’s board originally envisioned. Revenue growth across the group is expected to remain relatively flat in FY27, meaning the earnings growth story is almost entirely dependent on cost discipline rather than top-line momentum. After a 93% vertical move in under six months, technical indicators also suggest the stock is in overbought territory, and the risk of a pullback is real.

CSL enters the final quarter of calendar 2026 as a stock that has completed a full sentiment reset, moving from a position of deep institutional distrust at A$90 to one of active accumulation above A$180. The structural recovery in plasma therapies, the clarity provided by FY27 guidance, and the discipline shown through cost cuts and capital returns have all helped shift sentiment, with bulls now eager to hold a break above A$180 in a meaningful way for the first time this year.